Another US patent litigation win for Orexo AB’s ZUBSOLV®
On 30 June 2023 the US District Court for the District of New Jersey ruled in favour of Orexo AB in its patent litigation against Sun in relation to ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII), with the Court ruling that Orexo’s patents are both valid and are infringed by Sun.